TransMedics Group, Inc. logo
TransMedics Group, Inc. (TMDX)
Compare

TransMedics Group, Inc. (TMDX) Average EV/Sales Ratio

EV/Sales Ratio

The current ev/sales ratio for TransMedics Group, Inc. (TMDX) is 5.12x as of Saturday, June 20, 2026, shown against its trailing averages.

Average EV/Sales Ratio Chart

TMDX EV/Sales Ratio Averages

EV/SALES RATIO CURRENT

5.12x

EV/SALES RATIO TTM

8.59x

EV/SALES RATIO 3Y

11.18x

EV/SALES RATIO 5Y

16.32x

EV/SALES RATIO 10Y

18.00x

EV/SALES RATIO 15Y

18.00x

EV/SALES RATIO 20Y

18.00x

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA
728 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Waleed H. Hassanein